ADVERTISEMENT

ASCO 2022 – High-quality data in rare tumours help defining the best treatment for Ewing sarcoma

Cristina Ferrario — Agenzia Zoe   |   Conference Report   |   07 June 2022
ADVERTISEMENT

Takeaway

  • High-dose ifosfamide was more effective at prolonging survival in recurrent and primary refractory Ewing sarcoma (RR-ES) compared to topotecan+cyclophosphamide, despite more discontinuations due to toxicities.
  •  Before this trial, it was not possible to identify the most effective or most toxic regimen.

 

Why this matters

  • 5-year survival for RR-ES...

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right